Fenofibrate Dosing and Monitoring in Adults with Hypertriglyceridemia

Renal Function–Based Dosing

In patients with mild‑to‑moderate renal impairment (eGFR 30–59 mL/min/1.73 m²), the ACC/AHA guidelines recommend not exceeding 54 mg of fenofibrate daily. 1
Fenofibrate is contraindicated in severe renal impairment (eGFR < 30 mL/min/1.73 m²), including patients on dialysis; therapy must be stopped if eGFR falls persistently below this threshold. 1
For chronic kidney disease stages 1–4, the American Journal of Kidney Diseases advises initiating fenofibrate at 54 mg daily, reassessing renal function and lipid response before any dose increase; doses should be minimized when creatinine clearance is < 50 mL/min, and the drug should be avoided in severe renal impairment. 2

Baseline assessment of serum creatinine and eGFR is required before starting fenofibrate (ACC/AHA). 1
Renal function should be re‑checked within 3 months of initiation and subsequently every 6 months (ACC/AHA). 1

Fenofibrate commonly produces reversible serum creatinine elevations of ~15–20 % without causing true renal injury (Canadian Cardiovascular Society). 3
The Canadian Cardiovascular Society recommends starting fibrates at the lowest available dose in patients with creatinine clearance 20–100 mL/min. 3

Elderly patients, especially those with diabetes or hypertension, have an increased risk of myopathy when fenofibrate is combined with statins (Canadian Cardiovascular Society). 3

Fenofibrate may be added to low‑ or moderate‑intensity statin therapy only when the anticipated benefit outweighs the risk, particularly for triglyceride levels ≥ 500 mg/dL (ACC/AHA). 1
Co‑administration of gemfibrozil with statins is prohibited because of a markedly increased risk of rhabdomyolysis (ACC/AHA). 1
When fenofibrate is used with statins, clinicians should maintain heightened vigilance for myopathy symptoms (ACC/AHA). 1
If myopathic symptoms appear, creatine kinase should be measured (Canadian Cardiovascular Society). 3
Fenofibrate‑statin therapy raises the risk of alanine aminotransferase elevations > 5 × the upper limit of normal (ACC/AHA). 4

The Endocrine Society recommends adding fenofibrate (or EPA) in type 2 diabetes patients already on statins who have residual triglycerides > 150 mg/dL and at least two additional cardiovascular risk factors. 5
Fenofibrate may reduce the progression of diabetic retinopathy independent of triglyceride levels (Endocrine Society). 5

Failure to assess renal function before prescribing fenofibrate is the most critical error (ACC/AHA). 1
Using standard doses in patients with eGFR 30–59 mL/min/1.73 m² violates ACC/AHA guidance; the dose must be capped at 54 mg daily. 1
Combining gemfibrozil with statins should be avoided; fenofibrate is the preferred fibrate if a combination is needed (ACC/AHA). 1
Renal monitoring must follow the baseline → 3‑month → every‑6‑months schedule (ACC/AHA). 1

Fenofibrate is contraindicated for all patients with an estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m², which includes individuals with end‑stage renal disease (ESRD) and those on dialysis. [KDOQI (American Society of Nephrology) guideline] 6

In ESRD patients with elevated triglycerides, therapeutic lifestyle changes (dietary modification, weight control, physical activity) should be the primary intervention. [KDOQI guideline] 6

The concurrent use of any fibrate (including fenofibrate) with a statin is prohibited in chronic kidney disease (CKD) patients because it markedly increases the risk of rhabdomyolysis. [KDOQI guideline] 6

Gemfibrozil has even less safety data than fenofibrate in advanced CKD and should likewise be avoided in this population. [KDOQI guideline] 6